Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL005
MIFTS: 50

Oral Candidiasis

Categories: Infectious diseases, Oral diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Candidiasis

About this section

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis 12 55 15 73
Thrush 12 76 3 15
Candidiasis of Mouth 12
Candidiasis, Oral 44
Oral Moniliasis 12
Equine Thrush 73
Thrush, Oral 12
Candidiasis 73
Oral Thrush 63

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Oral diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:14262
ICD10 33 B37.0 B37.9
ICD9CM 35 112.0
MeSH 44 D002180
NCIt 50 C28137
SNOMED-CT 68 78048006 79740000
Sources

Summaries for Oral Candidiasis

About this section
PubMed Health : 63 About oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans.Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to candidiasis and vaginitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Innate Immune System and Defensins. The drugs Fluticasone and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and colon.

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives in the digestive tract and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth.

Wikipedia : 76 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Sources

Related Diseases for Oral Candidiasis

About this section

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 candidiasis 31.6 DEFB4A HTN3 SKAP2
2 vaginitis 30.1 CXCL8 DEFB4A
3 vulvovaginal candidiasis 29.9 DEFB1 DEFB4A
4 candida glabrata 29.7 HTN3 SKAP2
5 severe combined immunodeficiency 11.2
6 jak3-deficient severe combined immunodeficiency 11.2
7 immunodeficiency 32b 11.1
8 reticular dysgenesis 11.1
9 median rhomboid glossitis 11.1
10 leukoplakia 10.3
11 human immunodeficiency virus infectious disease 10.3
12 corneal abscess 10.2 DEFB1 DEFB4A
13 microsporidiosis 10.2 DEFA1 DEFB4A
14 osteonecrosis of the jaw 10.2 DEFB1 DEFB4A
15 dermatophytosis 10.2 DEFB4A LTF
16 cervicitis 10.2 CXCL8 DEFB4A
17 oral hairy leukoplakia 10.2
18 vaginal disease 10.2 CXCL8 DEFB4A
19 pouchitis 10.2 CXCL8 LTF
20 felty syndrome 10.2 CXCL8 LTF
21 giant papillary conjunctivitis 10.1 CXCL8 LTF
22 haemophilus influenzae 10.1 CXCL8 LTF
23 sinusitis 10.1 CXCL8 DEFB4A
24 localized scleroderma 10.1 DEFB1 DEFB4A
25 septic arthritis 10.1 CXCL8 DEFB4A
26 leukoregulin 10.1 CXCL8 IL1A
27 scabies 10.1 CXCL8 IL1A
28 aseptic meningitis 10.1 CXCL8 LTF
29 acquired immunodeficiency syndrome 10.1
30 multidrug-resistant tuberculosis 10.1 DEFA1 IL1A
31 radiculopathy 10.1 CXCL8 IL1A
32 gastritis 10.1 CXCL8 DEFB1 DEFB4A
33 bacterial infectious disease 10.1 CXCL8 DEFB1 DEFB4A
34 neurofibromatosis, type ii 10.1 DEFB1 DEFB4A IL1A
35 pulpitis 10.0 CXCL8 IL1A
36 diabetes mellitus 10.0
37 leukemia 10.0
38 mucositis 10.0
39 keratoconjunctivitis sicca 10.0 IL1A LTF
40 sebaceous gland disease 10.0 CXCL8 DEFB4A IL1A
41 bullous keratopathy 10.0 CXCL8 IL1A
42 bacterial vaginosis 10.0 CXCL8 DEFB4A IL1A
43 tibial neuropathy 10.0 B2M SKAP2
44 tarsal tunnel syndrome 10.0 B2M SKAP2
45 aggressive periodontitis 10.0 CXCL8 IL1A LTF
46 opportunistic mycosis 10.0 SKAP2 ST5
47 acute leukemia 10.0
48 shigellosis 10.0 CXCL8 LTF
49 dysentery 10.0 IL1A LTF TMPO
50 pyelitis 10.0 B2M CXCL8

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 37)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety
Bronchitis Bronchopneumonia
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Conn's Syndrome Decubitus Ulcer
Deficiency Anemia Dysthymic Disorder
Esophageal Candidiasis Esophagitis
Familial Atrial Fibrillation Glossitis
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Ischemic Heart Disease Neutropenia
Osteoporosis Paralytic Ileus
Peripheral Vascular Disease Pharyngitis
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis
Sources

Symptoms & Phenotypes for Oral Candidiasis

About this section

UMLS symptoms related to Oral Candidiasis:


oral manifestations
Sources

Drugs & Therapeutics for Oral Candidiasis

About this section

PubMedHealth treatment related to Oral Candidiasis: 63

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
4
Zinc Approved, Investigational Phase 4 7440-66-6
5
Methotrexate Approved Phase 4,Phase 3 59-05-2, 1959-05-2 126941
6
Aluminum hydroxide Approved, Investigational Phase 4,Phase 1,Phase 2 21645-51-2
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
8
Povidone Approved Phase 4 9003-39-8
9
Promethazine Approved, Investigational Phase 4 60-87-7 4927
10
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
11
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
14
Simethicone Approved Phase 4 8050-81-5
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
16 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
17
Salmeterol xinafoate Phase 4,Phase 3 94749-08-3 56801
18 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
19 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
22 Adrenergic Agents Phase 4,Phase 3,Phase 2
23 Autonomic Agents Phase 4,Phase 3,Phase 2
24 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
25 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
26 Respiratory System Agents Phase 4,Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Bronchodilator Agents Phase 4,Phase 3,Phase 2
32 Sympathomimetics Phase 4,Phase 3
33 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
34 Adrenergic Agonists Phase 4,Phase 3,Phase 2
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
39 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
41 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
43 Isophane insulin, beef Phase 4
44 Isophane Insulin, Human Phase 4
45 Hypoglycemic Agents Phase 4
46 Insulin, Isophane Phase 4
47 insulin Phase 4
48 Insulin, Short-Acting Phase 4
49 Insulin, Globin Zinc Phase 4
50 Antacids Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
2 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
3 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
4 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
5 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
6 Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
7 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
8 Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Completed NCT00002446 Phase 3 Posaconazole;Fluconazole
9 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
10 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed NCT01427738 Phase 3 Gentian Violet;Nystatin oral suspension
11 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Completed NCT02818803 Phase 3 Miconazole
12 Effect of Probiotic Lozenge on Gingivitis and Periodontitis Completed NCT02203812 Phase 3 Probiotic Arm;Placebo Arm
13 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
14 Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Completed NCT02175771 Phase 3 Fp MDPI;FS MDPI;FLOVENT HFA;ADVAIR DISKUS;albuterol/salbutamol HFA
15 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3 Nystatin
16 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed NCT01018186 Phase 3 Fluticasone Furoate/GW642444;Fluticasone propionate
17 Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Completed NCT00152867 Phase 3 Dexamethasone
18 Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy Completed NCT02181335 Phase 3 Respimat® Budesonide low dose;Respimat® Budesonide high dose;Turbohaler® Budesonide;Placebo
19 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02345161 Phase 3 Triple FF/UMEC/VI;Placebo to match FF/UMEC/VI;Budesonide/Formoterol;Placebo to match Budesonide/Formoterol combination;Albuterol/salbutamol
20 A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
21 Prophylactic Antibiotics in Measles Completed NCT00168532 Phase 3 Sulfamethoxazole-Trimethoprim
22 A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma Completed NCT02040779 Phase 3 Beclomethasone dipropionate breath-actuated inhaler;Placebo breath-actuated inhaler;albuterol/salbutamol
23 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
24 A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. Recruiting NCT02635438 Phase 3 Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
25 Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
26 Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate Unknown status NCT01087476 Phase 2 Doxycycline hyclate
27 Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis Completed NCT00659971 Phase 2 PAC113
28 A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole Completed NCT00001065 Phase 2 Amphotericin B
29 Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches Completed NCT00835029 Phase 2 Clotrimazole varnish;Clotrimazole troches
30 Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin Completed NCT02525458 Phase 2
31 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications Completed NCT01576718 Phase 2 Fp MDPI;Flovent Diskus;albuterol/salbutamol
32 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
33 Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure Completed NCT00168116 Phase 2
34 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids Completed NCT01479621 Phase 2 Fp MDPI;Flovent Diskus;albuterol/salbutamol;Placebo MDPI
35 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy. Completed NCT00603746 Phase 2 GW685698X
36 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy. Completed NCT00603382 Phase 2 GW685698X;Placebo
37 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy. Completed NCT00603278 Phase 2 GW685698X;placebo
38 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis Recruiting NCT02315898 Phase 2 Treatment-inhaled tPA
39 CelAgace™ OraRinse Solution for Treatment of Candidiasis Enrolling by invitation NCT03250923 Phase 1, Phase 2 silver citrate complex and acemannan
40 Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole Terminated NCT00005920 Phase 2 L-743,872
41 Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas Terminated NCT00967226 Phase 2 propranolol;Prednisolone
42 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
43 The Effect of Palatal Brushing on Denture Stomatitis Completed NCT01643876 Phase 1
44 Sinovuyo Caring Families Project - Pilot Trial Completed NCT01802294 Phase 1
45 Modified Directly Observed Antiretroviral Therapy Unknown status NCT01985269 Not Applicable
46 Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy Completed NCT00768794 Not Applicable
47 Novel Rinse to Treat in Oral Candidiasis in Cancer Patients Completed NCT00612963 Frio Oral Rinse
48 Oral Candida in Infants and Dietary Type Completed NCT01438983
49 The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection Completed NCT00001448
50 Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC Completed NCT00002057 Not Applicable Nystatin

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: candidiasis, oral

Sources

Genetic Tests for Oral Candidiasis

About this section
Sources

Anatomical Context for Oral Candidiasis

About this section

MalaCards organs/tissues related to Oral Candidiasis:

41
Tongue, Skin, Colon, Brain, Myeloid, Bone, Tonsil
Sources

Publications for Oral Candidiasis

About this section

Articles related to Oral Candidiasis:

(show top 50) (show all 654)
# Title Authors Year
1
Genotyping of Candida albicans and Candida dubliniensis by 25S rDNA analysis shows association with virulence attributes in oral candidiasis. ( 30321765 )
2019
2
Th17 cells differentiated with mycelial membranes of Candida albicans prevent oral candidiasis. ( 29462298 )
2018
3
Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. ( 29380647 )
2018
4
VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. ( 29788070 )
2018
5
Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. ( 29797142 )
2018
6
IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms. ( 29891557 )
2018
7
Promising alternative therapeutics for oral candidiasis. ( 29852856 )
2018
8
Chair-Side Direct Microscopy Procedure for Diagnosis of Oral Candidiasis in an Adolescent. ( 29854484 )
2018
9
Prevalence and association of oral candidiasis with dysphagia in individuals with acquired brain injury. ( 29182379 )
2018
10
Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study. ( 29949638 )
2018
11
Clinical and laboratorial features of oral candidiasis in HIV-positive patients. ( 29972567 )
2018
12
Dynamic changes of Th1/Th2/Th17 cytokines and human beta defensin 2 in HIV-infected patients with oral candidiasis during the first year of highly active anti-retroviral therapy. ( 29753928 )
2018
13
In Vivo Comparative Evaluation of the Pomegranate (Punica granatum) Peel Extract as an Alternative Agent to Nystatin against Oral Candidiasis. ( 29892147 )
2018
14
Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. ( 30096698 )
2018
15
A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer: Is topical steroid therapy a risk factor for oral candidiasis? ( 30383690 )
2018
16
Buccal Bullfrog (Rana catesbeiana Shaw) Oil Emulsion: A Mucoadhesive System Intended for Treatment of Oral Candidiasis. ( 30513861 )
2018
17
Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats. ( 30069501 )
2018
18
Antimicrobial Photodynamic Therapy Mediated by Curcumin-Loaded Polymeric Nanoparticles in a Murine Model of Oral Candidiasis. ( 30126245 )
2018
19
Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient. ( 30155394 )
2018
20
A single-center 18-year experience with oral candidiasis in Brazil: a retrospective study of 1,534 cases. ( 30231172 )
2018
21
A 61-Year-Old Caribbean Man With Thrush and Acute Respiratory Failure. ( 30044750 )
2018
22
Potential disruption of seed dispersal in the absence of a native Kauai thrush. ( 29381764 )
2018
23
A new insight into the classification of dusky thrush complex: bearings on the phylogenetic relationships within the Turdidae. ( 29457530 )
2018
24
How social media meet patients’ questions: YouTube™ review for children oral thrush. ( 29460525 )
2018
25
Oral Thrush. ( 29730363 )
2018
26
Long-term changes in migration timing of Song Thrush Turdus philomelos at the southern Baltic coast in response to temperatures on route and at breeding grounds. ( 29804234 )
2018
27
Neonatal Thrush Is Not Associated with Mode of Delivery. ( 29986979 )
2018
28
Quantity of Candida Colonies in Saliva: a8"A Diagnostic Evaluation for Oral Candidiasis. ( 28232964 )
2017
29
Development and Evaluation of Buccal Films Based on Chitosan for the Potential Treatment of Oral Candidiasis. ( 28108973 )
2017
30
Oral health: Asthma and oral candidiasis. ( 29123274 )
2017
31
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
32
Treatment and Prevention of Oral Candidiasis in Elderly Patients. ( 28566666 )
2017
33
Volatile organic compounds in the breath of oral candidiasis patients: a pilot study. ( 28601915 )
2017
34
The potential management of oral candidiasis using anti-biofilm therapies. ( 28818264 )
2017
35
Inherited IL-12RI^1 Deficiency in a Child With BCG Adenitis and Oral Candidiasis: A Case Report. ( 29025965 )
2017
36
Assessment of Effectiveness of Fluconazole and Clotrimazole in Treating Oral Candidiasis Patients: A Comparative Study. ( 28462176 )
2017
37
A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. ( 28783552 )
2017
38
Oral candidiasis: A retrospective study of 276 Brazilian patients. ( 29391707 )
2017
39
Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. ( 28748027 )
2017
40
Antifungal activity of linalool in cases of Candida spp. isolated from individuals with oral candidiasis. ( 28977047 )
2017
41
Topical Antimycotics for Oral Candidiasis in Warfarin Users. ( 27901310 )
2017
42
The assembly and annotation of the complete Rufous-bellied thrush mitochondrial genome. ( 26679427 )
2017
43
Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients. ( 27188880 )
2017
44
On the importance of geographic and taxonomic sampling in phylogeography: A reevaluation of diversification and species limits in a Neotropical thrush (Aves, Turdidae). ( 28347888 )
2017
45
Division within the North American boreal forest: Ecological niche divergence between the Bicknell's Thrush (Catharus bicknelli) and Gray-cheeked Thrush (C. minimus). ( 28770067 )
2017
46
Elimination of oral candidiasis may increase stimulated whole salivary flow rate. ( 27497081 )
2016
47
Molecular analysis of fungal populations in patients with oral candidiasis using next-generation sequencing. ( 27305838 )
2016
48
Elucidating the Role of Hyposalivation and Autoimmunity in Oral Candidiasis. ( 27998016 )
2016
49
Adjuvant antifungal therapy using tissue tolerable plasma on oral mucosa and removable dentures in oral candidiasis patients: a randomised double-blinded split-mouth pilot study. ( 26932256 )
2016
50
Treatment of Oral Candidiasis Using PhotodithazineAr- Mediated Photodynamic Therapy In Vivo. ( 27253525 )
2016
Sources

Variations for Oral Candidiasis

About this section
Sources

Expression for Oral Candidiasis

About this section
Search GEO for disease gene expression data for Oral Candidiasis.
Sources

Pathways for Oral Candidiasis

About this section

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.4 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3
2
Defensins 66
Show member pathways
 11.38 DEFA1 DEFB1 DEFB4A HTN3 LTF
3
Pertussis 37
11.01 CXCL8 IL1A IRF8
4
Interleukin-10 signaling 66
10.95 CXCL8 IL1A
Sources

GO Terms for Oral Candidiasis

About this section

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
2 Golgi lumen GO:0005796 9.33 DEFA1 DEFB1 DEFB4A
3 extracellular region GO:0005576 9.23 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
2 chemotaxis GO:0006935 9.78 CXCL8 DEFA1 DEFB1 DEFB4A
3 defense response GO:0006952 9.73 CXCL8 DEFA1 DEFB1 DEFB4A
4 cellular response to lipopolysaccharide GO:0071222 9.72 CXCL8 DEFA1 IRF8
5 defense response to Gram-positive bacterium GO:0050830 9.69 DEFA1 DEFB1 DEFB4A
6 defense response to Gram-negative bacterium GO:0050829 9.67 DEFA1 DEFB1 DEFB4A LTF
7 antibacterial humoral response GO:0019731 9.63 DEFA1 DEFB1 LTF
8 defense response to bacterium GO:0042742 9.63 DEFA1 DEFB1 DEFB4A HTN3 IRF8 LTF
9 killing of cells of other organism GO:0031640 9.62 DEFA1 DEFB4A HTN3 LTF
10 retina homeostasis GO:0001895 9.58 B2M LTF
11 innate immune response in mucosa GO:0002227 9.58 DEFA1 DEFB1 LTF
12 iron ion homeostasis GO:0055072 9.57 B2M LTF
13 defense response to fungus GO:0050832 9.56 DEFA1 HTN3
14 defense response to protozoan GO:0042832 9.54 DEFA1 IRF8
15 response to molecule of bacterial origin GO:0002237 9.52 B2M CXCL8
16 membrane disruption in other organism GO:0051673 9.49 DEFA1 LTF
17 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.35 CXCL8 DEFA1 DEFB1 DEFB4A LTF
18 antimicrobial humoral response GO:0019730 9.02 DEFA1 DEFB1 DEFB4A HTN3 LTF

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A
Sources

Sources for Oral Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....